IRIS
FOGARI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.099
EU - Europa 1.651
AS - Asia 1.165
SA - Sud America 4
AF - Africa 2
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.924
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.078
CN - Cina 1.148
IE - Irlanda 490
UA - Ucraina 428
FI - Finlandia 244
DE - Germania 235
SE - Svezia 112
IT - Italia 71
GB - Regno Unito 37
CA - Canada 21
RU - Federazione Russa 8
ES - Italia 7
FR - Francia 6
IN - India 6
IR - Iran 5
NL - Olanda 5
CO - Colombia 3
HU - Ungheria 2
JP - Giappone 2
MU - Mauritius 2
RO - Romania 2
TR - Turchia 2
AU - Australia 1
BH - Bahrain 1
BR - Brasile 1
EU - Europa 1
GR - Grecia 1
LV - Lettonia 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
TH - Thailandia 1
Totale 4.924
Salva come PNG Salva come JPEG
Città #
Jacksonville 537
Dublin 490
Chandler 444
Nanjing 344
Nanchang 157
Ashburn 128
Shenyang 119
Hebei 117
Princeton 102
Wilmington 102
Lawrence 98
Medford 94
Changsha 93
Jiaxing 70
Hangzhou 69
Boardman 64
Beijing 61
Tianjin 56
Helsinki 47
Seattle 24
Toronto 19
Woodbridge 19
Norwalk 15
Fairfield 12
Milan 11
Ann Arbor 9
Des Moines 9
Genova 9
Jinan 9
Bruino 8
Kunming 7
New York 6
Ningbo 6
Shanghai 6
Washington 6
Lanzhou 5
Alcobendas 4
Eindhoven 4
Los Angeles 4
Pune 4
Verona 4
Bogotá 3
Bruchsal 3
Fuzhou 3
Saint Petersburg 3
Zhengzhou 3
Budapest 2
Changchun 2
Guangzhou 2
Houston 2
Kochi 2
Leawood 2
Monza 2
Novokuznetsk 2
Orange 2
Parma 2
Pavia 2
Siena 2
Tappahannock 2
Ardabil 1
Auburn Hills 1
Backa Topola 1
Bangkok 1
Bloomfield 1
Calgary 1
Dalby 1
Düzce 1
Edmond 1
Ellsworth 1
Esfahan 1
Exeter 1
Falkenstein 1
Hazlet 1
Henagar 1
Issy-les-moulineaux 1
Jinhua 1
Kilburn 1
Las Vegas 1
Manama 1
Menlo Park 1
Misinto 1
Mosgiel 1
Munich 1
Oklahoma City 1
Orzivecchi 1
Osaka 1
Paris 1
Phoenix 1
Redmond 1
Rockville 1
Rome 1
Rotterdam 1
Skopje 1
São Paulo 1
Taizhou 1
Valencia 1
Yurga 1
Totale 3.471
Salva come PNG Salva come JPEG
Nome #
A randomized, placebo-controlled study about the effect of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters 121
Effects of berberis aristata/silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients 75
Differential effect of candesartan and olmesartan on adipose tissue activity biomarkers in type 2 diabetic hypertensive patients 74
A possible way to improve the glycemic control and the beta cell function during three years: the triple therapy. 72
A multicenter, randomised, single-blind study on the effects of exenatide or glimepiride on insulin resistance. 69
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome 67
Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus 67
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients 64
Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients 63
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. 63
n-3 PUFAs on metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients after euglycemic clamp and oral fat load. 63
Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. 61
Different actions of losartan and ramipril on adipose tissue Activity and vascular remodeling biomarkers in hypertensive patients 61
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 61
Berberis aristata/silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients 61
A comparison between sitagliptin or glibenclamide in addition to metformin+pioglitazone on glycemic control and beta-cell function: the triple oral therapy 61
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 60
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 60
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load 59
Olmesartan/amlodipine combination vs olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients 59
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial 58
Effetti di un carico lipidico orale sui marcatori di infiammazione e stress endoteliale nei soggetti sani 58
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia during omega-3 polyunsaturated fatty acids therapy 58
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial 57
Sitagliptin in aggiunta alla precedente terapia ipoglicemizzante sull'insulino-resistenza e il profilo lipidico: uno studio a due anni 57
Efficacia e sicurezza di pioglitazone o rosiglitazone in combinazione con metformina in pazienti con diabete di tipo 2 e sindrome metabolica 57
Adipocytokines levels in obese and non-obese subjects, an observational study 57
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome 56
Impact of the glyco-metabolic control on erectile dysfunction in patients with type 2 diabetes mellitus 55
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 55
Pioglitazone paragonato a glibenclamide sul profilo lipidico e i parametri infiammatori nei pazienti diabetici di tipo 2 in terapia con metformina durante un carico orale di grassi 55
Effetti di un carico lipidico orale sui marcatori di rimodellamento vascolare nei soggetti sani 55
Valutazione dei livelli di metalloproteasi 2 e 9 e dei loro inibitori nei soggetti con dislipidemia combinata 55
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 54
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 54
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 54
A randomized, double blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. 54
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone 53
Moxonidine action on glucose and lipid metabolism in hypertensive patients with metabolic syndrome 53
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 53
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients 53
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. 53
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 52
Effect of valsartan on insulin sensitivity, leptin, and BMI in hypertensive obese patients 52
Efficacia e sicurezza del pioglitazone o rosiglitazone in combinazione con metformina su pazienti diabetici dislipidemici 52
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients 51
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation 51
Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes 50
Exenatide or glimepiride on insulin resistance in type 2 diabetic patients 50
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 50
Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients 50
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type2 diabetic patients not well controlled by metformin 50
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone: a double-blind, randomised clinical trial 49
Exenatide paragonato a glimepiride in aggiunta a metformina sul controllo glicemico, l’insulino-resistenza e i parametri infiammatori in pazienti diabetici di tipo 2 49
Variation of some inflammatory markers in hypertensive patients after one year of olmesartan/amlodipine single pill combination compared to olmesartan or amlodipine monotherapies. 49
Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study 49
Effetti di una combinazione di vildagliptin + metformina su alcuni parametri di funzionalità β-cellulare e di insulino-resistenza in uno studio a 12 mesi 48
Effetti di exenatide in combinazione con metformina sulla funzione beta-cellulare in pazienti affetti da diabete mellito di tipo 2 48
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 48
Valutazione dei livelli delle metalloproteasi 2 e 9 e dei loro inibitori nella dislipidemia combinata durante terapia con acidi grassi polinsaturi 48
Effetti di sitagliptin rispetto a glibenclamide in aggiunta a metformina e pioglitazone in pazienti diabetici di tipo 2 48
Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared to olmesartan or amlodipine monotherapies 47
Pioglitazone o rosiglitazone in associazione con metformina nei pazienti con diabete mellito di tipo 2 e sindrome metabolica: effetto sui fattori di rischio cardiovascolare convenzionali e non convenzionali 47
Effetti di acarbose sui parametri infiammatori e di insulino-resistenza durante un carico orale di grassi 47
Doxazosin improves blood pressure and metabolic parameters in impaired glucose tolerance patients in therapy with acarbose 47
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients 46
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: A randomized placebo-controlled trial 46
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. 46
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation 46
Una possibilità per migliorare il controllo glicemico e la funzionalità β-celllare durante tre anni di studio: la triplice terapia 45
Vildagliptin action on some adipocytokines levels in type 2 diabetic patients: a 12 months, placebo-controlled study 45
Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients 45
Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction 44
Exenatide plus metformin compared to metformin alone on beta cell function in type 2 diabetic patients. 44
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation 44
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 43
Variation of some inflammatory biomarkers after the addition of sitagliptin in type 2 diabetic patients not controlled by metformin 43
Modificazioni ultrasonografiche del tessuto adiposo viscerale e sottocutaneo dopo terapia con pioglitazone o glibenclamide in combinazione con rosuvastatina in pazienti diabetici di tipo 2 non ben controllati da metformina 42
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. 41
Studio randomizzato, in doppio cieco, placebo-controllato sugli effetti di sitagliptin sui parametri di insulino-resistenza e di funzionalità beta-cellulare. 41
Effetti di pioglitazone paragonato a glibenclamide sul profilo lipidico e i parametri infiammatori nei pazienti diabetici di tipo 2 in terapia con metformina dopo un carico orale di grassi 41
Comparison of vildagliptin and glimepiride: effects on glycemic control, fat tolerance, and inflammatory markers in people with type 2 diabetes 41
A randomized, double blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetic patients already treated with pioglitazone and metformin: a three years study 41
Valutazione dei livelli di MMP-2, MPP-9 e dei loro inibitori nella iperlipemia combinata 40
Valsartan improves plasma leptin in hypertensive obese patients 38
Sitagliptin added to previously taken anti-diabetic agents on glycemic control and lipid profile 37
Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies 37
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial 37
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 36
Vildagliptin Added to Metformin on β-Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients 35
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 35
Matrix metalloproteinase-2, -9, and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy 32
Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months 30
Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2 years study 30
Efficacy of simvastatin and fenofibrate association in hypercholesterolemic, type 2 diabetic patients compared to monotherapy 30
Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load 29
The effects of canrenone in patients with metabolic syndrome 25
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes 23
Totale 4.965
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.310
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.310
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 0 1
2019/20201.429 388 616 1 81 0 91 7 88 0 123 34 0
2020/2021754 96 80 17 82 0 100 6 123 17 111 104 18
2021/2022366 0 0 18 3 3 3 2 25 21 2 58 231
2022/20231.364 130 93 1 91 161 150 0 90 571 17 40 20
2023/2024389 45 98 15 31 41 102 7 39 6 4 1 0
Totale 4.965